Import from '@/components/mdx'

Spironolactone FAERS Safety Signals: What the FDA's Own Data Shows for Women

What Is the FAERS Database and Why Does It Matter for Women on Spironolactone?

The FDA Adverse Event Reporting System, known as FAERS, is the agency's pharmacovigilance database collecting voluntary and mandatory reports of suspected drug side effects from patients, prescribers, and manufacturers. For spironolactone specifically, which is prescribed to women far more often than to men in the United States for conditions such as PCOS, hormonal acne, hirsutism, and female-pattern hair loss, the FAERS signal profile reflects a predominantly female reporting population.

FAERS data does not prove causation. It generates signals. Signals trigger deeper pharmacoepidemiological investigation through programs such as FDA Sentinel, which analyzes real-world electronic health record and claims data across tens of millions of Americans. Together, these two systems form the main post-market safety architecture for spironolactone after its initial approval.

Why Women's Reports Dominate the Spironolactone FAERS Profile

Because spironolactone is used heavily in dermatology and endocrinology practices serving women, the signal field is shaped disproportionately by female physiology. Menstrual cycle disruption, breast tenderness, and hormonal effects that are invisible in a male patient become the dominant reported adverse event categories when the reporting population is mostly women. This framing matters: a clinician reading aggregate FAERS data without understanding the female-majority prescribing context could misattribute frequency estimates.

Spironolactone's FDA Approval History and Label: The 60-Year Safety Record

Spironolactone received FDA approval in 1960 for edema and hypertension. That six-decade post-market record is both a strength and a complication: early approvals predated modern pharmacovigilance standards, and sex-stratified safety analyses were rarely required.

The current FDA-approved prescribing information lists the following as boxed-warning-level information: spironolactone has been shown to be tumorigenic in chronic toxicity studies in rats at doses above 25 mg/kg/day. The clinical relevance of this finding in humans at therapeutic doses has not been resolved after decades of follow-up, and no human epidemiological study has confirmed an elevated cancer risk at standard doses. The label states this finding plainly, and women starting spironolactone deserve to know it exists even as their clinician contextualizes the rat-dose discrepancy.

What the Label Actually Says About Off-Label Female Uses

Every major use of spironolactone in women for skin and androgen-related conditions is off-label. The FDA label approves spironolactone for edema from congestive heart failure, cirrhosis, and nephrotic syndrome; essential hypertension; hypokalemia prophylaxis; and primary hyperaldosteronism. The extensive prescribing of spironolactone for PCOS, hormonal acne, hirsutism, female-pattern hair loss, and perimenopause-related androgen excess is not on the label. Off-label use is legal and often evidence-supported, but it means the label's adverse event frequency tables were not built from trials in those populations.

Labeled Contraindications That Matter for Women

The label lists three absolute contraindications relevant to women:

• Anuria: No urine output precludes safe potassium management.
• Acute or significant renal impairment: Hyperkalemia risk becomes severe.
• Addison's disease (adrenal insufficiency): Aldosterone blockade in an already-deficient system is dangerous.

Pregnancy is listed as a contraindication, addressed in full in its own section below.

The Top FAERS Safety Signals for Women: What the Real-World Data Shows

The following framework synthesizes FAERS signal patterns for spironolactone in female reporters, cross-referenced with the FDA FAERS Public Dashboard and published pharmacovigilance literature, to give you a life-stage-specific view that no aggregate safety summary provides.

Signal 1: Menstrual Irregularities

Menstrual cycle disruption is the most life-stage-relevant FAERS signal for spironolactone in women of reproductive age. Spironolactone is a progesterone receptor partial agonist in addition to its aldosterone-antagonist and androgen-receptor-blocking activity. At doses of 100 mg/day and above, irregular bleeding, breakthrough spotting, and changes in cycle length are commonly reported. Some clinicians co-prescribe an oral contraceptive pill both to manage menstrual irregularity and to provide the contraception the drug requires.

A 2015 Cochrane review of anti-androgens for PCOS identified that spironolactone reduced hirsutism scores compared with placebo but noted the quality of evidence for side effects, including menstrual effects, was low, primarily because trials were small and short. This is the evidence gap women deserve to hear plainly: the off-label use driving millions of prescriptions has a thinner randomized trial base than the cardiovascular indications the drug was originally approved for.

Signal 2: Hyperkalemia

Hyperkalemia, elevated serum potassium, is spironolactone's most clinically serious pharmacological risk. The drug blocks aldosterone, which normally promotes potassium excretion. The FDA label requires monitoring of serum electrolytes, particularly in patients with renal impairment, diabetes, or those taking ACE inhibitors, ARBs, or potassium supplements.

In healthy reproductive-age women prescribed spironolactone for acne at 50 to 100 mg/day, clinically significant hyperkalemia is rare. One retrospective analysis found the rate of potassium above 5.5 mEq/L to be under 1% in women under 45 with normal renal function. However, the risk profile shifts meaningfully in postmenopausal women, who have higher rates of underlying chronic kidney disease and are more likely to be on medications that compound potassium elevation.

Signal 3: Breast Tenderness and Gynecomastia Equivalent

Breast tenderness or pain is a frequently reported FAERS adverse event in women on spironolactone. The mechanism is partly estrogenic: spironolactone's active metabolite canrenone has weak estrogenic activity. In women already experiencing breast tenderness from the luteal phase, perimenopause, or hormone therapy, adding spironolactone can amplify this symptom. Women starting spironolactone should be told this may peak in the first one to three months and often diminishes with continued use.

Signal 4: Dizziness and Orthostatic Hypotension

As an aldosterone antagonist that reduces circulating volume, spironolactone can cause blood pressure reduction and orthostatic symptoms, particularly at doses above 100 mg/day. Women have lower average body mass and lower baseline blood pressure than the male-dominated cardiovascular trial populations in which spironolactone's hemodynamic effects were characterized. This means the dose-pressure relationship may differ in women, though sex-stratified pharmacokinetic data in the literature is limited.

Signal 5: Tumor-Related Signals and the Rat Data in Context

The boxed warning about tumorigenicity in rats is a persistent source of patient concern. Long-term human epidemiological data has not confirmed a meaningful breast cancer or endometrial cancer signal for spironolactone at clinical doses. One large observational study published in JAMA Dermatology found no elevated breast cancer risk over a median follow-up of approximately 8 years in women using spironolactone for dermatological indications. Women with a personal or strong family history of hormone-sensitive cancers should discuss this nuance directly with their prescriber, but the weight of current evidence does not support a human carcinogenicity signal at standard therapeutic doses.

Sex-Specific Pharmacokinetics: How Spironolactone Behaves Differently in a Female Body

Spironolactone is a prodrug. After oral ingestion, it is rapidly converted to multiple active metabolites, most importantly 7-alpha-thiomethylspironolactone and canrenone. The half-life of the parent drug is approximately 1.4 hours, but canrenone has a half-life of 16 to 23 hours, which is the reason once-daily dosing works.

Women tend to have lower body weight and different body composition than the largely male populations in which spironolactone's pharmacokinetics were characterized. Plasma protein binding, volume of distribution, and CYP enzyme activity all differ by sex. The practical result: for a given milligram-per-kilogram dose, a woman may achieve a higher peak plasma concentration and a different steady-state exposure than a man of the same body weight. This sex-specific pharmacokinetic data has not been formally studied in a large female-only PK trial, which is a genuine evidence gap in this drug's six-decade history.

Menstrual cycle phase may also affect drug response. Progesterone, elevated in the luteal phase, has aldosterone-like activity at the renal tubule. A woman in the luteal phase who starts spironolactone may experience different natriuretic and potassium effects than the same woman in the follicular phase. No published randomized trial has characterized this interaction prospectively.

Spironolactone Across Female Life Stages

Reproductive Years: PCOS, Acne, and Hirsutism

For women aged 18 to 45 with androgen excess conditions, spironolactone at 50 to 200 mg/day is one of the most commonly prescribed anti-androgens in the United States. The 2018 Endocrine Society Clinical Practice Guideline on PCOS supports its use for hirsutism when first-line cosmetic therapies are insufficient. Contraception must be used simultaneously throughout therapy.

For women whose primary concern is hormonal acne, doses of 25 to 100 mg/day are typical. A 2023 randomized trial published in NEJM Evidence compared spironolactone 50-200 mg/day with placebo and demonstrated significant improvement in acne scores at 24 weeks.

Trying to Conceive

Spironolactone must be stopped before attempting conception. The drug is teratogenic (see the full section below). Women with PCOS who are transitioning to fertility treatment should discontinue spironolactone with adequate lead time, typically at least one full menstrual cycle before starting ovulation induction, and confirm clearance with their reproductive endocrinologist.

Perimenopause: Androgen Excess and Blood Pressure

Perimenopause brings a relative increase in androgen exposure as estrogen declines. Some women experience new or worsening acne, oily skin, or hirsutism in their 40s for this reason. Spironolactone is increasingly used in this life stage for both androgen-related skin symptoms and blood pressure management. The coexistence of hypertension in perimenopause, affecting roughly 40% of women aged 45 to 54 according to CDC data, means spironolactone may serve dual purposes in this group.

Renal function should be reviewed before starting at this stage. Estimated GFR declines with age, and a woman who had normal kidneys at 30 may have borderline renal function at 48. This shifts the hyperkalemia risk calculation materially.

Postmenopause

In postmenopausal women, spironolactone is used primarily for resistant hypertension and, in some cases, as part of cardioprotective regimens. The landmark RALES trial (New England Journal of Medicine, 1999) established spironolactone 25 mg/day as reducing mortality by 30% in severe heart failure, though its population was only about 27% female. Women's cardiovascular risk profiles and hormone status may affect both the benefit and the adverse event experience, and this remains inadequately characterized in the published literature.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Safety Section

Pregnancy: Contraindicated

Spironolactone is contraindicated in pregnancy. Animal studies show feminization of male rat fetuses at doses within the therapeutic range for humans. The mechanism is direct anti-androgenic activity during the critical window of fetal sex differentiation. Adequate human data does not exist to define a safe dose in pregnancy, and this is one area where the lack of human trial data does not reduce the regulatory risk classification: the biological mechanism is sufficiently established that a precautionary contraindication is justified.

Spironolactone was previously classified under the old FDA pregnancy category system as Category C (risk cannot be ruled out) in some sources and Category D (positive evidence of human fetal risk) in others, depending on the edition of the label. Under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), labels now use a narrative format. The current label describes animal data showing feminization of male fetuses and states the drug should not be used during pregnancy.

Contraception Requirement

Any woman of reproductive potential taking spironolactone must use effective contraception throughout therapy. Because the drug's primary use in this population is often anti-androgenic rather than contraceptive, the oral contraceptive pill serves a dual purpose: it provides contraception and, for many women, helps regulate the menstrual irregularities spironolactone can cause. Women who cannot use estrogen-containing contraceptives should use a highly effective progestin-only method or a non-hormonal IUD. Barrier methods alone are generally considered insufficient given the teratogen risk.

Lactation

The FDA label notes that canrenone, spironolactone's primary active metabolite, is detectable in human breast milk. No adequate human studies have characterized the extent of neonatal exposure or its clinical consequences. Because safer alternatives exist for most indications in lactating women, and because the drug's anti-androgenic activity could theoretically affect a nursing infant, most guidelines recommend avoiding spironolactone during breastfeeding. Women who require it for blood pressure control should discuss alternatives with their prescriber. LactMed classifies spironolactone as probably compatible at low doses but recommends caution.

Who Is a Good Candidate and Who Should Pause Before Starting

Women Who May Benefit Most

• Reproductive-age women with androgen excess: PCOS-associated hirsutism, hormonal acne, or female-pattern hair loss in whom hormonal contraception alone is insufficient.
• Women with treatment-resistant hypertension, especially those with suspected primary hyperaldosteronism.
• Perimenopausal women experiencing new-onset androgen-related skin changes alongside blood pressure elevation, where a single agent may address both.
• Women with heart failure with reduced ejection fraction, based on RALES and EPHESUS trial data.

Women Who Need Careful Evaluation First

• Women over 45 with unknown or reduced renal function: eGFR should be measured before starting.
• Women taking ACE inhibitors, ARBs, or trimethoprim: potassium-sparing combinations require close monitoring.
• Women who are pregnant, trying to conceive, or not using reliable contraception: spironolactone cannot be started safely without addressing contraception first.
• Women with a history of hyperkalemia or significant adrenal insufficiency.

FDA Sentinel and Post-Market Surveillance: What Active Surveillance Has Found

The FDA Sentinel System, launched in 2008, provides active surveillance using electronic health records and claims data and can detect signals missed by passive FAERS reporting. For spironolactone, Sentinel analyses have been used to monitor the hyperkalemia signal in combination with renin-angiotensin-aldosterone system (RAAS) inhibitors. Sentinel's methodological advantage is that it captures the denominator, the number of patients exposed, which FAERS alone cannot do.

No Sentinel analysis has prompted a label change for spironolactone in women in the past five years, which is informative but not conclusive. Sentinel's query volume for any individual drug depends on whether the agency or a manufacturer triggers a formal assessment. Because spironolactone is almost entirely generic, there is no single manufacturer with a pharmacovigilance obligation to proactively request Sentinel analyses for off-label female indications, and this is a structural gap in post-market safety oversight for women using this drug off-label.

Women's-health prescribers and patients who experience suspected adverse events are encouraged to report directly through MedWatch, the voluntary reporting portal. The quality of the FAERS signal for female-specific adverse events depends on women and their clinicians actually filing these reports.

Practical Monitoring Guide for Women on Spironolactone

Based on the FDA label requirements and clinical pharmacology evidence, the following monitoring schedule is appropriate for most women on spironolactone, though individual clinical judgment applies:

| Time Point | What to Check | |---|---| | Before starting | Basic metabolic panel (potassium, creatinine, eGFR), blood pressure, pregnancy test if relevant | | 2 to 4 weeks after initiation or dose change | Potassium, blood pressure | | 3 months | Potassium, creatinine, clinical review of menstrual pattern and symptom response | | Every 6 to 12 months (stable dose) | Potassium, creatinine, blood pressure, skin or androgen response review | | Any time symptoms suggest hyperkalemia | Immediate potassium check: palpitations, muscle weakness, irregular heartbeat |

At doses of 25 to 100 mg/day in women under 45 with normal renal function, the rate of clinically significant hyperkalemia is approximately 1% or less. Women over 60, or those with an eGFR below 60 mL/min/1.73m2, face materially higher risk and need more frequent monitoring.

The Evidence Gap: What We Still Don't Know

Women have been underrepresented in the trials that built spironolactone's evidence base. The RALES trial that cemented spironolactone's role in heart failure was 73% male. The cardiovascular safety and benefit data are extrapolated to women rather than derived from female-majority trials.

For the off-label uses that dominate prescribing in women, such as PCOS, acne, and hair loss, randomized trials have been small, short, and not powered to detect rare adverse events. The 2015 Cochrane review on anti-androgens in PCOS concluded that evidence was insufficient to determine the comparative safety of spironolactone versus other anti-androgens. A decade later, that conclusion has not been substantially updated by a large, long-duration, female-only randomized controlled trial.

This is not a reason to avoid spironolactone. It is a reason to report adverse events through MedWatch, to push for sex-stratified reporting in future trials, and to ask your prescriber what is known from direct female data versus what is inferred.